MEDVIA’s Carry members voted in favor of the proposed merger with life sciences cluster flanders.bio. The vote was held during an Extraordinary General Assembly and New Year reception on 27 January at PwC in Machelen.
The motion to merge with flanders.bio was passed with a near 96% majority, with 22 Carry member present voting in favor and one voting against. There were no abstentions. Only MEDVIA’s Carry members have voting rights.
Flanders.bio’s members will be asked to vote in February. The outcome of this vote will determine whether the two organizations will ultimately merge.
Why a merger?
As Flanders’ healthtech spearhead cluster, MEDVIA represents medtech, biotech and digital health companies, assisting them to rapidly provide high-quality, novel health products to the global public. With more than 340 members, flanders.bio is a European leader in the life science cluster landscape.
The merger allows MEDVIA and flanders.bio to align activities and deliver more powerful support for our collective members. We will be able to achieve greater impact by offering broader, more dynamic networking opportunities, better directed funding for R&D in healthtech and biotech collaborations and increased efficiency, sharpening our focus in common areas.
MEDVIA will update our members as to the outcome of flanders.bio’s vote when it takes place next month.